{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:30:02Z","timestamp":1789173002280,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejso.2025.110120","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T02:09:55Z","timestamp":1746151795000},"page":"110120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enhancing surgical precision in ovarian cancer with FR\u03b1-fluorescence-guided surgery"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0726-1687","authenticated-orcid":false,"given":"Filippo Alberto","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ceccaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-9464","authenticated-orcid":false,"given":"Matteo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5527-4370","authenticated-orcid":false,"given":"Nicolas","family":"Bourdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raspagliesi","family":"Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Bogani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.110120_bib1","unstructured":"Cancer of the Ovary - Cancer Stat Facts. In: SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html. Accessed 5 December 2024."},{"key":"10.1016\/j.ejso.2025.110120_bib2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/ijgc-2022-004101","article-title":"Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)","volume":"32","author":"Gaba","year":"2022","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ejso.2025.110120_bib3","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejso.2025.110120_bib4","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.2174\/0929867326666190816232330","article-title":"Translational theragnosis of ovarian cancer: where do we stand?","volume":"27","author":"Perrone","year":"2020","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ejso.2025.110120_bib5","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110120_bib6","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.110120_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ygyno.2018.03.043","article-title":"Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: an NRG Oncology\/Gynecologic Oncology Group study","volume":"149","author":"Eskander","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2025.110120_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","article-title":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","volume":"34","author":"Bogani","year":"2024","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ejso.2025.110120_bib9","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","article-title":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FR\u03b1-high platinum-sensitive ovarian cancer","volume":"20","author":"O'Malley","year":"2024","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.ejso.2025.110120_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112842","article-title":"Intraoperative tumor detection using pafolacianine","volume":"23","author":"Dindere","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2025.110120_bib11","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/med.22027","article-title":"Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery","volume":"44","author":"Solidoro","year":"2024","journal-title":"Med Res Rev"},{"key":"10.1016\/j.ejso.2025.110120_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmech.2019.06.039","article-title":"Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection","volume":"179","author":"Scilimati","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ejso.2025.110120_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/ph15060668","article-title":"Fluorochrome selection for imaging intraoperative ovarian cancer probes","volume":"15","author":"Perrone","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejso.2025.110120_bib14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-\u03b1 targeting: first in-human results","volume":"17","author":"van Dam","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2025.110120_bib15","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.ejso.2025.110120_bib16","unstructured":"Ottawa Hospital Research Institute. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 27 December 2024."},{"key":"10.1016\/j.ejso.2025.110120_bib17","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1021\/acs.molpharmaceut.7b00464","article-title":"Improved intraoperative detection of ovarian cancer by folate receptor alpha targeted dual-modality imaging","volume":"14","author":"Hekman","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejso.2025.110120_bib18","author":"Tanyi"},{"key":"10.1016\/j.ejso.2025.110120_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11307-024-01914-0","article-title":"In vivo labeling and detection of circulating tumor cells in mice using OTL38","volume":"26","author":"Pace","year":"2024","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.ejso.2025.110120_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1021\/acsnano.6b06796","article-title":"Folate-targeted surface-enhanced resonance Raman scattering nanoprobe ratiometry for detection of microscopic ovarian cancer","volume":"11","author":"Oseledchyk","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejso.2025.110120_bib21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.7150\/thno.6413","article-title":"Biologically-targeted detection of primary and micro-metastatic ovarian cancer","volume":"3","author":"Liu","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.ejso.2025.110120_bib22","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1158\/1078-0432.CCR-15-2640","article-title":"A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer","volume":"22","author":"Hoogstins","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejso.2025.110120_bib23","author":"Hoogstins"},{"key":"10.1016\/j.ejso.2025.110120_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2019.07.010","article-title":"A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer","volume":"155","author":"Randall","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2025.110120_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.22.00291","article-title":"A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor-positive ovarian cancer (study 006)","volume":"41","author":"Tanyi","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110120_bib26","doi-asserted-by":"crossref","first-page":"32144","DOI":"10.18632\/oncotarget.8282","article-title":"Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17","volume":"7","author":"Tummers","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2025.110120_bib27","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1021\/acs.jmedchem.8b01115","article-title":"Evaluation of novel tumor-targeted near-infrared probe for fluorescence-guided surgery of cancer","volume":"61","author":"Mahalingam","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejso.2025.110120_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41551-020-0536-7","article-title":"Multispectral image-guided surgery in patients","volume":"4","author":"Choi","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.ejso.2025.110120_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41698-024-00699-3","article-title":"Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence","volume":"8","author":"Cheng","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ejso.2025.110120_bib30","article-title":"Can fluorescence-guided surgery improve optimal surgical treatment for ovarian cancer? A systematic scoping review of clinical studies","volume":"33","author":"St","year":"2023","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.ejso.2025.110120_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/cancers17030410","article-title":"Fluorescence-guided surgery to detect microscopic disease in ovarian cancer: a systematic review with meta-analysis","volume":"17","author":"Erdemoglu","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejso.2025.110120_bib32","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/cancers15030966","article-title":"Development of a novel intra-operative score to record diseases' anatomic fingerprints (ANAFI score) for the prediction of complete cytoreduction in advanced-stage ovarian cancer by using machine learning and explainable artificial intelligence","volume":"15","author":"Laios","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejso.2025.110120_bib33","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20221031","article-title":"Clinical applications of artificial intelligence in radiology","volume":"96","author":"Mello-Thoms","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ejso.2025.110120_bib34","first-page":"133","article-title":"Artificial intelligence in gastrointestinal endoscopy: a comprehensive review","volume":"37","author":"Ali","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.ejso.2025.110120_bib35","article-title":"The use of artificial intelligence for complete cytoreduction prediction in epithelial ovarian cancer: a narrative review","volume":"30","author":"Parpinel","year":"2023","journal-title":"Cancer Control J Moffitt Cancer Cent"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325005487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:40:55Z","timestamp":1755495655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325005487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0748798325005487"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110120","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing surgical precision in ovarian cancer with FR\u03b1-fluorescence-guided surgery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110120"}}